
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV demonstrates a positive outlook due to its advancing gene therapy pipeline, notably with AMT-130 for Huntington's disease and AMT-191 for Fabry disease, which are showing credible progress toward regulatory approval. The company’s financial metrics indicate increased investment in its operations, with SG&A expenses rising to $21.6 million, suggesting a commitment to growth and development. Furthermore, the enhancements to its asset portfolio and a strong balance sheet position uniQure favorably for strategic opportunities, reinforcing investor confidence in its multi-faceted approach to treating severe genetic diseases.
Bears say
uniQure NV faces significant financial challenges due to its status as a clinical-stage company that has yet to bring a revenue-generating product to market, resulting in continuous losses since its inception. Additionally, the company is vulnerable to market competition from both existing and emerging therapies that target similar indications, which can adversely affect its market penetration and pricing strategies. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization timelines may prolong development periods and escalate associated costs, further straining the company's financial position.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares